Lupin inks pact with Phil for bacterial vaginosis drug Solosec
Solosec is designed to be a single dose treatment for patients with bacterial vaginosis.;
Mumbai, Baltimore: Drugmaker, Lupin Pharmaceuticals Inc., has recently announced a partnership with Phil, Inc., which helps deliver cost-effective next-generation access solutions for patients who are prescribed Solosec (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women.
Solosec is the only single 2g oral dose therapy for the most common vaginal infection in the U.S. among adult women. This treatment is designed to deliver a full course of therapy in just one packet.
In November, Lupin announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Solosec (secnidazole) for the treatment of trichomoniasis in adults and adolescents. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of June 30, 2021.
"With the addition of Solosec to the Phil platform, we are able to provide a convenient channel for physicians to prescribe Solosec and enhance the patient experience," said Jon Stelzmiller, President - Specialty, Lupin Pharmaceuticals, Inc. "We are proud that Lupin has been at the forefront of advancing affordable healthcare for women globally for decades and we are committed to helping prevent and manage women's health conditions, including BV."
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.